AAAS 1239 |
HIV Vaccine |
I |
April 2019 |
United States of America |
Men, Women |
10E8.4/iMab |
Ongoing |
HVTN 139 |
HIV Vaccine |
I |
November 2021 |
South Africa |
Men, Women |
AdC6-HIVgp140, AdC7-HIVgp140, CH505TF, GLA-SE, gp120 |
Ongoing |
ANRS VRI06 |
HIV Vaccine |
I |
March 2021 |
France, Switzerland |
Men, Women |
CD40.HIVRI.Env, DNA-HIV-PT123, Poly-ICLC |
Ongoing |
RV 460 |
HIV Vaccine |
I |
March 2021 |
Kenya |
Men, Women |
Env gp145 C.6980 protein, Env-C Plasmid DNA, Rehydragel, ALF43, dmLT |
Ongoing |
RV 546 |
HIV Vaccine |
I |
January 2022 |
|
Men |
IHV01 A244, AHFG ALFQ adjuvant |
Ongoing |
HVTN 135 |
HIV Vaccine |
I |
November 2020 |
South Africa |
Adolescent/Children |
CH505TF, GLA-SE, gp120 |
Ongoing |
HIV-CORE 006 |
HIV Vaccine |
I |
August 2021 |
Kenya, Rwanda, Uganda, Zambia |
Men, Women |
ChAdOx1.tHIVconsv1, MVA.tHIVcnsv4, MVA.tHIVconsv3 |
Ongoing |
IAVI C101 |
HIV Vaccine |
I |
August 2020 |
United States of America, Netherlands |
Men, Women |
BG505 SOSIP GT1.1 gp140 |
Ongoing |
ACTHIVE-001 |
HIV Vaccine |
I |
November 2019 |
Netherlands |
Men |
ConM SOSIP.v7, gp140 |
Ongoing |
19-I-0069 |
HIV Vaccine |
I |
April 2019 |
United States of America |
Men, Women |
Ad4-Env150KN, VRC-HIVRGP096-00-VP, Ad4-Env145NFL |
Ongoing |
WHV 138 |
HIV Vaccine |
I |
July 2021 |
United States of America |
Men |
DNA , Protein |
Ongoing |
VIR-111-2001 |
HIV Vaccine |
I |
December 2020 |
United States of America |
Men, Women |
|
Ongoing |
HVTN 140/ HPTN 101 |
HIV Vaccine |
Open Label |
November 2021 |
United States of America, Kenya, South Africa, Zimbabwe |
Men |
PGDM1400LS, PGT121.414.LS, VRC07-523LS |
Ongoing |
HVTN 136/ HPTN 092 |
HIV Vaccine |
I |
November 2020 |
United States of America |
Men, Women |
PGT121.414.LS, VRC07-523LS |
Ongoing |
IAVI G003 |
HIV Vaccine |
I |
May 2022 |
South Africa, Rwanda |
Men, Women |
mRNA-1644 (eOD-GT8 60mer) |
Ongoing |
HVTN 302 |
HIV Vaccine |
Open Label |
February 2022 |
United States of America |
Men, Women |
BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA |
Ongoing |
HVTN 300 |
HIV Vaccine |
I |
May 2021 |
United States of America |
Men |
CH505TF |
Ongoing |
IAVI G002 |
HIV Vaccine |
I |
November 2021 |
United States of America |
Men, Women |
mRNA-1644 (eOD-GT8 60mer) |
Ongoing |
HVTN 706/ HPX3002/ Mosaico |
HIV Vaccine |
III |
October 2019 |
United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain |
Men |
Ad26.Mos4.HIV, gp140 |
Ongoing |
PrEPVacc / PV1 |
HIV Vaccine, PrEP |
IIb |
January 2020 |
Uganda, South Africa, United Republic of Tanzania, Mozambique |
Men, Women |
DNA , MVA, Protein |
Ongoing |